Evidence map›Paper›PMID 31581580›Full record

ReviewViruses2019

Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses.

Eric J Yager, Kouacou V Konan

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Measles virus reprograms CD4Frontiers in cell and developmental biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. The Implication of Sphingolipids in Viral Infections.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Eric J YagerDepartment of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA. Eric.Yager@acphs.edu.
Kouacou V KonanDepartment of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208-3479, USA. KonanK@amc.edu.
Albany College of Pharmacy and Health Sciences · USAlbany Medical Center Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several notable human diseases are caused by enveloped RNA viruses: influenza, AIDS, hepatitis C, dengue hemorrhagic fever, microcephaly, and Guillain-Barré Syndrome. Being enveloped, the life cycle of this group of viruses is critically dependent on host lipid biosynthesis. Viral binding and entry involve interactions between viral envelope glycoproteins and cellular receptors localized to lipid-rich regions of the plasma membrane. Subsequent infection by these viruses leads to reorganization of cellular membranes and lipid metabolism to support the production of new viral particles. Recent work has focused on defining the involvement of specific lipid classes in the entry, genome replication assembly, and viral particle formation of these viruses in hopes of identifying potential therapeutic targets for the treatment or prevention of disease. In this review, we will highlight the role of host sphingolipids in the lifecycle of several medically important enveloped RNA viruses.

Indexed as

AnimalsCell MembraneGlycosphingolipidsHepacivirusHepatitis CHIVHumansLipid MetabolismLipidsRNA VirusesSphingolipidsViral Envelope ProteinsVirionVirus AttachmentVirus ReplicationGlycosphingolipidsLipidsSphingolipidsViral Envelope Proteinsantiviralglycosphingolipidslipid biosynthesissphingolipidsviruses

Identifiers

PMID31581580
PMCPMC6832137
OpenAlexW2978897652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.